期刊文献+

P53在散发性乳腺癌中的表达 被引量:2

原文传递
导出
摘要 目的:探讨P 53蛋白表达在散发性乳腺癌中的作用。方法:收集86例乳腺癌及癌旁组织、48例乳腺增生症手术标本,采用免疫组化S-P法检测P 53蛋白在各例中的表达情况。结果:P 53在乳腺癌、乳腺癌旁组织、乳腺增生症中的阳性率分别为37.2%(32/86)、16.3%(14/86)和8.3%(4/48),三组间比较,差异有统计学意义。结论:P 53蛋白异常表达在散发性乳腺癌发生、发展过程中起着一定作用。
作者 马金柱 罗力
出处 《中国误诊学杂志》 CAS 2009年第7期1551-1552,共2页 Chinese Journal of Misdiagnostics
  • 相关文献

参考文献4

  • 1Mitsudomi T, Hamajima N, Ogawa M, et al. Prognostic significance of P53 alternations in patients with non small cell lung cancer[J]. A Meta-analysis Clin Cancer Res, 2000,6 (10) : 4055.
  • 2Montero S, Guzman C, Vargas C, et al. Prognostic value of cytosolic P53 protein in breast cancer[J]. Tumor Biol,2001,22(5) :337.
  • 3Ostrakhovitch EA,Cherian MG. Role of P53 and reactive oxygen species in apoptotic response to copper and Iinc in epithelial breast cancer[J. Apoptosis,2005,10(1): 111-112.
  • 4Davidoff AM, Kerns BJ, Pence JC, et al. P53 alterations in all stages of breast cancer[J]. Surg Oncol, 1991,48 (4) : 260-267.

同被引文献37

  • 1Penauh - Llorca F, Abrial C, Mouret - Reynier MA, et al. Achieving higher pathological complete response rates in HER2 - positive pa- tients with induction chemotherapy without trastuzumab in operable breast cancer [J]. Oncologlst, 2007, 12 (4): 390-396.
  • 2Arriola E, Moreno A, Varela M, et al. Predictive value of HER2 and topoisomerase Ⅱ alpha in response to primarydoxoruhicin in breast cancer [J]. EurJ Cancer, 2006, 42 (17): 2954-2960.
  • 3Dahabreh IJ, Linardou H, Siannis F, et al. Trastuzumab in the adjuvant treatment of earlvstage breast cancels, a svstematic review recta - analysis of randomized controlled trials [ J ]. Oneologist, 2008, 13: 620-630.
  • 4Lazaridis G, Pentheroudakis G, Pavlidis N. Integrating wastuzumab in the neoadjuvant treatment of primary breast canc: accumulating evi- dence of efficacy, synergy and safety [ J]. Crit Rev Oneol Hematol, 2008, 66 (1): 31-41.
  • 5Gong Y, Sweet W, Duh YJ, et al. Chromogenic in situ hydfidization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/ CAP recommendations [J]. Am J Clin Pathol, 2009, 131 (4) : 490 -497.
  • 6Deo SV, Bhutani M, Shukla NK, et al. Randomized trial comparing neo- adjuvant versus adjuvant chemotherapy in operable locally ad- vanced breastcancer (T4b N 0 - 2 M 0) [ J ]. J Surg Oncol, 2003, 84 (4): 192-197.
  • 76Ganem G, Tubiana - Hulin M, Fumoleau P, et al. Phase II trial eom - bining docetaxel and doxorubicin as neoadjuvant chemotherapy in pa- tients with operable breast cancer [ J]. Ann Oncol, 2003, 14 (11) : 1623 - 1628.
  • 8Lee SH, Chung MA, Quddus MR. The effect of neoadjuvant ehemo - therapy on estrogen and progesterone receptor expression and hormonal receptor status in breast eanee [J]. Am J Surg, 2003, 186 (4): 384 - 350.
  • 9Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer [J]. J Clin Oncol, 2007, 25 (33) : 5287 -5312.
  • 10Fernandez - Morales LA, Segui MA, Andreu X, et al. Analysis of the pathologic response to primary chemotherapyin patients with locally ad- vanced breast cancer grouped according to estrogen receptor, progester- one receptor, and Her-2 status [J]. Clin Breast Cancer, 2007, 7 (7) : 559 - 564.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部